Adherex Technologies (FENC) Stock Price, News & Analysis

Company Overview

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Key Stats

• Today's Range: $8.35 to $8.61
• 50-Day Range: $5.63 to $8.54
• 52-Week Range: $3.96 to $8.72
• Volume: 114,106 shs
• Average Volume: 92,401 shs
• Market Capitalization: $235.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

Adherex Technologies Stock Analysis - MarketRank™

Adherex Technologies scored higher than 50% of companies evaluated by MarketBeat, and ranked 585th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Adherex Technologies has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Adherex Technologies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adherex Technologies are expected to decrease in the coming year, from ($0.11) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adherex Technologies is -16.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adherex Technologies is -16.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.91% of the float of Adherex Technologies has been sold short.

Short Interest Ratio / Days to Cover

Adherex Technologies has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Adherex Technologies has recently decreased by 4.23%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adherex Technologies does not currently pay a dividend.

Dividend Growth

Adherex Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.91% of the float of Adherex Technologies has been sold short.

Short Interest Ratio / Days to Cover

Adherex Technologies has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Adherex Technologies has recently decreased by 4.23%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Adherex Technologies has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

MarketBeat Follows

Only 1 people have added Adherex Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Adherex Technologies insiders have sold 84.89% more of their company's stock than they have bought. Specifically, they have bought $104,602.00 in company stock and sold $193,400.00 in company stock.

Percentage Held by Insiders

11.76% of the stock of Adherex Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.51% of the stock of Adherex Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FENC Stock Analysis - Frequently Asked Questions

How have FENC shares performed this year?

Adherex Technologies' stock was trading at $6.32 on January 1st, 2025. Since then, FENC shares have increased by 35.1% and is now trading at $8.54.
View the best growth stocks for 2025 here.

How were Adherex Technologies' earnings last quarter?

Adherex Technologies Inc. (NASDAQ:FENC) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.08. The business earned $8.51 million during the quarter, compared to analyst estimates of $8.18 million.
Read the conference call transcript.

How do I buy shares of Adherex Technologies?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adherex Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adherex Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/02/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FENC
• CIK: 1211583
• Web: www.fennecpharma.com
• Phone: 919-636-4530
• Fax: 919-890-0490
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $13.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +53.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$440 thousand
• Net Margins: -45.52%
• Pretax Margin: -45.53%
• Return on Equity: N/A
• Return on Assets: -26.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.13
• Quick Ratio: 4.97

Sales & Book Value

• Annual Sales: $47.54 million
• Price / Sales: 4.92
• Cash Flow: $0.03 per share
• Price / Cash Flow: 257.00
• Book Value: ($0.21) per share
• Price / Book: -40.38

Miscellaneous

• Outstanding Shares: 27,600,000
• Free Float: 24,570,000
• Market Cap: $234.05 million
• Optionable: Optionable
• Beta: 0.39